MCL1 and Miyoshi myopathy: In addition, while STAT3 inhibition with AG-490, a JAK-2 tyrosin kinase inhibitor, was not able to abrogate the effect of MM-CM on MDSC proliferation (data not shown), the Mcl-1 inhibitor MIM1 was able to completely abrogate the effect of MM-CM on the viability of murine CD11b+ cells.